• Explore /
  • Poster
  • / Subgroup analyses of a phase 1/2 study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC).

Subgroup analyses of a phase 1/2 study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC).

Abstract Poster

Authors

null

Masafumi Ikeda

Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Chiba, Japan

Masafumi Ikeda , Kenji Ikeda , Masatoshi Kudo , Yukio Osaki , Takuji Okusaka , Toshiyuki Tamai , Takuya Suzuki , Takashi Hisai , Hideaki Miyagishi , Kiwamu Okita , Hiromitsu Kumada

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Translational Research

Clinical Trial Registration Number

NCT00946153

Citation

J Clin Oncol 35, 2017 (suppl 4S; abstract 309)

DOI

10.1200/JCO.2017.35.4_suppl.309

Abstract #

309

Poster Bd #

E1

Abstract Disclosures

Similar Posters

First Author: Kiwamu Okita

First Author: Philippe Merle

First Author: Arndt Vogel

First Author: Catherine Roberts